Burosumab Efficacy and Safety in Patients with X-Linked Hypophosphatemia: Systematic Review and Meta-analysis of Real-World Data.

Burosumab Meta-analysis Systematic review X-linked hypophosphatemia XLH

Journal

Calcified tissue international
ISSN: 1432-0827
Titre abrégé: Calcif Tissue Int
Pays: United States
ID NLM: 7905481

Informations de publication

Date de publication:
15 Jul 2024
Historique:
received: 15 02 2024
accepted: 18 06 2024
medline: 15 7 2024
pubmed: 15 7 2024
entrez: 15 7 2024
Statut: aheadofprint

Résumé

To assess the efficacy and safety of burosumab in children and adults with X-linked hypophosphatemia based on real-world evidence. MEDLINE (via PubMed) and Cochrane Library were searched until 18 October 2023 for single-arm (before-after) studies. Registries including Clinicaltrials.gov, EU Clinical Trials, WHO International Clinical Trials Registry Platform, and conference abstracts. The outcomes were a change in serum phosphorus concentrations and change in RSS, a change in serum ALP, bone-specific ALP, a change in the ratio of Tubular maximum reabsorption of Phosphate to Glomerular Filtrate rate, a change in serum 1,25(OH)

Identifiants

DOI: 10.1007/s00223-024-01250-z PMID: 39008126
pubmed: 39008126
doi: 10.1007/s00223-024-01250-z
pii: 10.1007/s00223-024-01250-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Beck-Nielsen SS, Mughal Z, Haffner D et al (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. https://doi.org/10.1186/s13023-019-1014-8
doi: 10.1186/s13023-019-1014-8 pubmed: 30808384 pmcid: 6390548
Ackah SA, Imel EA (2023) Approach to hypophosphatemic rickets. J Clin Endocrinol Metab 108:209–220. https://doi.org/10.1210/clinem/dgac488
doi: 10.1210/clinem/dgac488
Fukumoto S (2021) FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. J Mol Endocrinol 66:R57–R65
doi: 10.1530/JME-20-0089 pubmed: 33295878
Carpenter TO, Imel EA, Holm IA et al (2011) A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381–1388
doi: 10.1002/jbmr.340 pubmed: 21538511
Chesher D, Oddy M, Darbar U et al (2018) Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41:865–876. https://doi.org/10.1007/s10545-018-0147-6
doi: 10.1007/s10545-018-0147-6 pubmed: 29460029 pmcid: 6133187
Whyte MP, Greenberg CR, Salman NJ et al (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366:904–913. https://doi.org/10.1056/nejmoa1106173
doi: 10.1056/nejmoa1106173 pubmed: 22397652
Linglart A, Imel EA, Whyte MP et al (2022) Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107:813–824. https://doi.org/10.1210/clinem/dgab729
doi: 10.1210/clinem/dgab729 pubmed: 34636899
Linglart A, Biosse-Duplan M, Briot K et al (2014) Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 3:R13–R30. https://doi.org/10.1530/ec-13-0103
doi: 10.1530/ec-13-0103 pubmed: 24550322 pmcid: 3959730
Wang S, Wang X, He M et al (2023) Efficacy and safety of burosumab in X-linked hypophosphatemia. J Clin Endocrinol Metab 109(1):293–302. https://doi.org/10.1210/clinem/dgad440
doi: 10.1210/clinem/dgad440 pubmed: 37497620
Insogna KL, Briot K, Imel EA et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1381–1382
doi: 10.1002/jbmr.3475
Carpenter TO, Imel EA, Ruppe MD et al (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Investig 124:1587–1597. https://doi.org/10.1172/JCI72829
doi: 10.1172/JCI72829 pubmed: 24569459 pmcid: 3973088
Padidela R, Whyte MP, Glorieux FH et al (2021) Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int 108:622–633. https://doi.org/10.1007/s00223-020-00797-x
doi: 10.1007/s00223-020-00797-x pubmed: 33484279 pmcid: 8064984
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097
doi: 10.1371/journal.pmed.1000097 pubmed: 19621072 pmcid: 2707599
www.metaxis.com . PROSPERO International prospective register of systematic reviews
Thacher TD, Pettifor JM, Tebben PJ et al (2019) Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic rickets severity score. Bone 122:76–81. https://doi.org/10.1016/j.bone.2019.02.010
doi: 10.1016/j.bone.2019.02.010 pubmed: 30772600
Thacher TD, Fischer PR, Pettifor JM et al (2000) Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr 46:132–139. https://doi.org/10.1093/tropej/46.3.132
doi: 10.1093/tropej/46.3.132 pubmed: 10893912
Bellamy NBWGCCJSLW (1998) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840
Rohatgi A (2021) WebPlotDigitizer Pacifica, California, USA [07/11/2021]. Version: 4.5. Available from: https://automeris.io/WebPlotDigitizer
Higgins JPT, Li T, Deeks JJ (eds) (2023) Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org/handbook
Deeks JJ, Higgins JPT, Altman DG (eds) (2023) Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org/handbook
Sterne JA, Hernán MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Online) 355:i4919. https://doi.org/10.1136/bmj.i4919
doi: 10.1136/bmj.i4919 pubmed: 27733354
Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT (2023) Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Available from www.training.cochrane.org/handbook
Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G et al (2016) Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods 7(1):55–79
doi: 10.1002/jrsm.1164 pubmed: 26332144
Sandy J (2019) Abstracts. Horm Res Paediatr 91:1–682. https://doi.org/10.1159/000501868
doi: 10.1159/000501868
Shammari AA (2021) Abstracts. Horm Res. Paediatr 94:1–445. https://doi.org/10.1159/000518849
doi: 10.1159/000518849
Baroncelli G (2022) Abstracts. Horm Res Paediatr 96:40
Zhukouskaya V (2019) Abstracts. Horm Res Paediatr 91:1–682
doi: 10.1159/000501868
Arcidiacono T, Foligno NE, Brioni E et al (2023) Different efficacy of burosumab on physical performance and serum phosphate in adult patients with X-linked hyphophosphatemic rickets during the first six-month of treatment. J Clin Med 12(8):2906. https://doi.org/10.3390/jcm12082906
doi: 10.3390/jcm12082906 pubmed: 37109242 pmcid: 10143203
Brener A, Lebenthal Y, Cleper R et al (2021) Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy. Ther Adv Endocrinol Metab. https://doi.org/10.1177/20420188211001150
doi: 10.1177/20420188211001150 pubmed: 33796255 pmcid: 7970173
Weber TJ, Imel EA, Carpenter TO et al (2023) Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia. J Clin Endocrinol Metab 108:155–165. https://doi.org/10.1210/clinem/dgac518
doi: 10.1210/clinem/dgac518
Whyte MP, Carpenter TO, Gottesman GS et al (2019) Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7:189–199. https://doi.org/10.1016/S2213-8587(18)30338-3
doi: 10.1016/S2213-8587(18)30338-3 pubmed: 30638856
Imel EA, Zhang X, Ruppe MD et al (2015) Prolonged correction of serum phosphorus in adults with x-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100:2565–2573. https://doi.org/10.1210/jc.2015-1551
doi: 10.1210/jc.2015-1551 pubmed: 25919461 pmcid: 4495171
Insogna KL, Rauch F, Kamenický P et al (2019) Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res 34:2183–2191. https://doi.org/10.1002/jbmr.3843
doi: 10.1002/jbmr.3843 pubmed: 31369697
Namba N, Kubota T, Muroya K et al (2022) Safety and efficacy of burosumab in pediatric patients with X-linked hypophosphatemia: a phase 3/4 open-label trial. J Endocr Soc. https://doi.org/10.1210/jendso/bvac021
doi: 10.1210/jendso/bvac021 pubmed: 35356008 pmcid: 8962727
Paloian NJ, Nemeth B, Sharafinski M et al (2022) Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 37:2667–2677. https://doi.org/10.1007/s00467-022-05484-7
doi: 10.1007/s00467-022-05484-7 pubmed: 35211790
Ruppe MD, Zhang X, Imel EA et al (2016) Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep 5:158–162. https://doi.org/10.1016/j.bonr.2016.05.004
doi: 10.1016/j.bonr.2016.05.004 pubmed: 28326356 pmcid: 4926842
Ewert A, Rehberg M, Schlingmann KP et al (2023) Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia. J Clin Endocrinol Metab 108:e998–e1006. https://doi.org/10.1210/clinem/dgad223
doi: 10.1210/clinem/dgad223 pubmed: 37097907
Martín Ramos S, Gil-Calvo M, Roldán V et al (2020) Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia. Front Pediatr 8:48. https://doi.org/10.3389/fped.2020.00048
doi: 10.3389/fped.2020.00048 pubmed: 32133333 pmcid: 7040476
Ruppe MD, Brosnan PG, Au KS et al (2011) Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets. Clin Endocrinol (Oxf) 74:312–318. https://doi.org/10.1111/j.1365-2265.2010.03919.x
doi: 10.1111/j.1365-2265.2010.03919.x pubmed: 21050253
Imel EA, Econs MJ (2005) Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol 16:2565–2575
doi: 10.1681/ASN.2005050573 pubmed: 16033853
Imel EA, Glorieux FH, Whyte MP et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. The Lancet 393:2416–2427. https://doi.org/10.1016/S0140-6736(19)30654-3
doi: 10.1016/S0140-6736(19)30654-3
Schindeler A, Biggin A, Munns CF (2020) Clinical evidence for the benefits of burosumab therapy for X-linked hypophosphatemia (XLH) and other conditions in adults and children. Front Endocrinol (Lausanne) 11:338
doi: 10.3389/fendo.2020.00338 pubmed: 32547492
Portale AA, Carpenter TO, Brandi ML et al (2019) Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 105:271–284. https://doi.org/10.1007/s00223-019-00568-3
doi: 10.1007/s00223-019-00568-3 pubmed: 31165191
Carpenter TO, Whyte MP, Imel EA et al (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987–1998. https://doi.org/10.1056/nejmoa1714641
doi: 10.1056/nejmoa1714641 pubmed: 29791829
Wang S, Wang X, He M et al (2023) Efficacy and safety of burosumab in X-linked hypophosphatemia. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgad440
doi: 10.1210/clinem/dgad440 pubmed: 37633261 pmcid: 11099479
Gentile C, Chiarelli F (2021) Rickets in children: an update. Biomedicines 9:738. https://doi.org/10.3390/biomedicines9070738
doi: 10.3390/biomedicines9070738 pubmed: 34199067 pmcid: 8301330
Lim R, Shailam R, Hulett R et al (2021) Validation of the radiographic global impression of change (RGI-C) score to assess healing of rickets in pediatric X-linked hypophosphatemia (XLH). Bone 148:115964. https://doi.org/10.1016/j.bone.2021.115964
doi: 10.1016/j.bone.2021.115964 pubmed: 33878504
Imel EA, Glorieux FH, Whyte MP et al (2023) Burosumab vs phosphate/active vitamin D in pediatric X-linked hypophosphatemia: a subgroup analysis by dose level. J Clin Endocrinol Metab 108(11):2990–2998. https://doi.org/10.1210/clinem/dgad230
doi: 10.1210/clinem/dgad230 pubmed: 37084401 pmcid: 10583998
Adam MP, Feldman J, Mirzaa GM (2012) X-linked hypophosphatemia synonyms: XLHR, X-linked hypophosphatemic rickets, X-linked vitamin D-resistant rickets summary clinical characteristics. GeneReviews® [Internet] https://www.ncbi.nlm.nih.gov/books/NBK1384/
D’Oronzo S, Brown J, Coleman R (2017) The role of biomarkers in the management of bone-homing malignancies. J Bone Oncol 9:1–9
doi: 10.1016/j.jbo.2017.09.001 pubmed: 28948139 pmcid: 5602513
Whyte MP (2020) Chapter 66 - Hypophosphatasia: nature’s window on alkaline phosphatase function in humans. In: Bilezikian JP, Martin TJ, Clemens TL, Rosen CJ (eds) Principles of bone biology (fourth edition). Academic Press, pp 1569–1599
doi: 10.1016/B978-0-12-814841-9.00066-X
Tripkovic L, Lambert H, Hart K et al (2012) Comparison of vitamin D2and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr 95:1357–1364
doi: 10.3945/ajcn.111.031070 pubmed: 22552031 pmcid: 3349454
Payne RB, Bijvoet O (1998) Renal tubular reabsorption of phosphate (TmPjGFR): indications and interpretation. Ann Clin Biochem 35(2):201–206
doi: 10.1177/000456329803500203 pubmed: 9547891
Salaffi F, Leardini G, Canesi B et al (2003) Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. Osteoarthr Cartil 11:551–560. https://doi.org/10.1016/S1063-4584(03)00089-X
doi: 10.1016/S1063-4584(03)00089-X
Organising Committee Nils Krone P, Paul Van Trotsenburg C 61st Annual meeting of the European Society for Paediatric Endocrinology (ESPE)

Auteurs

Damiani Kiafzezi (D)

Postgraduate Program "Research Methodology in Medicine and Health Sciences", Aristotle University of Thessaloniki, Thessaloniki, Greece. kiafdami@gmail.com.

Athina Stamati (A)

School of Medicine, Faculty of Health Science, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Thomas Karagiannis (T)

Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Diabetes Centre, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Dimitrios G Goulis (DG)

Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, 541 24, Thessaloniki, Greece.

Athanasios Christoforidis (A)

1st Paediatric Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Ippokratio General Hospital, Thessaloniki, Greece.

Classifications MeSH